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Abstract
Background: Breast density is known to affect breast cancer risk and screening sensitivity, but it may also be
associated with breast cancer survival. The interpretation of results from previous studies on breast density and
survival is complicated by the association between detection mode and survival. Here, we studied the effect of
breast density on breast cancer-specific survival for different detection modes (screen-detected, interval ≤ 24
or > 24 months, non-participant).
Methods: Data from the Nijmegen (Dutch) breast cancer screening programme were used. Women diagnosed
with invasive breast cancer between 1975 and 2011 were included. Breast density was assessed visually, based on a
dichotomized Wolfe scale: ‘fatty breasts’ (≤25%) and ‘dense breasts’ (> 25%). Cox proportional hazard regression was
used to obtain hazard ratios (HR).
Results: We identified 2742 eligible women, with a breast pattern available for 2233 women. A diagnosis of interval
cancer (HR 2.06, 95% CI 1.62–2.61) led to a significantly increased risk of breast cancer death compared with screen-
detected cancer. No significant cause-specific survival difference between women with dense and fatty breasts was
observed (HR 0.94, 95% CI 0.77–1.15). The hazard was only higher for women with dense breasts among interval
cancers ≤24 m (HR 1.07, 95% CI 0.74–1.56). The hazard appeared to be lower for women with dense breasts than for
women with fatty breasts among screen-detected (HR 0.77, 95% CI 0.53–1.11) and interval cancers > 24 m (HR 0.80,
95% CI 0.53–1.20). None of the effects were statistically significant.
Conclusions: Detection mode is strongly associated with breast cancer death. No clear association is apparent
between breast density and breast cancer death, regardless of detection mode.
Keywords: Breast cancer survival, Screening, Breast density, Detection mode
Background
Fibroglandular breast tissue is radiodense and appears as
white areas on a mammogram. High breast density, i.e.,
a high proportion of dense tissue, has been associated
with an increased breast cancer risk. The relative risk is
estimated at 4 to 6 when women with more than 75%
dense tissue are compared with women with less than
25% dense tissue [1]. In addition, dense breast tissue
masks tumours on mammograms: tumour detection is
decreased when breast density is high [2]. This results in
a lower programme sensitivity in breast cancer screening
in women with dense breasts.
It is unclear to what degree breast density is associated
with breast cancer survival. Two different hypotheses
may be suggested. High breast density delays cancer de-
tection due to the masking effect [2]. Tumours occur-
ring in dense breasts may thus on average have
progressed to a higher stage, with worse prognostic
characteristics, at diagnosis. This would affect breast
cancer survival. Some studies have indeed observed an
association between high breast density and indicators
of tumour progression, although results are inconclusive
[3–7]. Examples include larger tumour size and lymph
node involvement.
The second hypothesis is based on an association with
tumour aggressiveness. The etiological pathway through
which breast density increases breast cancer risk is un-
known. Breast tumours often originate from epithelial
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tissue. A higher number of epithelial cells and a poten-
tially increased proliferation in dense tissue may thus ex-
plain the association, although an important role for the
stromal tissue has also been suggested [8, 9]. Whether
the natural history of these tumours differs from tu-
mours arising in fatty breasts has, however, not been de-
termined. Some breast cancer risk factors (e.g., body-
mass index [BMI] and several reproductive factors) are
known to affect the risk of tumour subtypes differently,
which may translate into a different disease prognosis
and breast cancer survival [10–12]. The evidence on
breast density and its possible involvement in pathways
that lead to more aggressive tumours is still ambiguous
[3–7, 13–18]. A higher tumour aggressiveness, as indi-
cated by tumour markers including hormone receptor
status, also results in higher stage at diagnosis and
poorer breast cancer survival.
The difficulty with survival analyses is that they may be
affected by lead time bias when the study is conducted in
a screening setting. Lead time is the time by which a
breast cancer diagnosis is advanced due to early detection
[19]. If survival time is measured as the time since diagno-
sis, the advanced diagnosis would increase survival time,
even without an actual effect on breast cancer survival.
Since the distribution of screen-detected and interval tu-
mours is expected to be different in women with high
breast density compared with women with low breast
density, this may affect survival estimates as well. To gain
more insight into these different effects, the association
between density and breast cancer survival could be stud-
ied separately for each detection mode, in addition to
studying overall breast cancer survival.
Previous studies have addressed the effect of breast
density on breast cancer survival or breast cancer mor-
tality, but the results have been inconclusive [20–28].
The studies by Chiu et al. and Olsson et al. appeared to
suggest an increased mortality in dense breasts, whereas
other studies found no significant difference or even ob-
served a potential survival benefit. Detection mode (i.e.,
screen-detected cancer, interval cancer, or cancer in
non-participants) was not taken into account in most of
these studies, apart from Olsson [21] and Eriksson [24],
making it difficult to compare results and explain the
observed differences.
In this study, we addressed the effect of breast density
pattern on breast cancer-specific survival. Breast cancer-
specific survival was studied for different modes of de-
tection, in order to remove or reduce the potential role
of lead and length time bias in our associations.
Methods
Population
The study was based on data from the Nijmegen (the
Netherlands) breast cancer screening population. A pilot
screening programme started here in 1975, with women
35 years or older being invited [29]. In 1989, a central-
ized nationwide programme was introduced in the
Netherlands. This programme was aimed at women 50
to 69 years old. The screening age in Nijmegen was
adapted accordingly. Since 1998, Dutch women aged 70
to 74 years also receive a screening invitation. The
current programme invites women 50 to 74 years to
mammographic screening every 2 years. Every mammo-
gram is read independently by two certified screening ra-
diologists. Women included in our study received at
least one screening invitation before their diagnosis. All
women consented to the use of their anonymous data
for scientific research.
Breast cancer patients
Women diagnosed with invasive breast cancer between
1975 and 2011, both via screening and outside the
screening programme, were included in our study.
Women were excluded if it was unclear if the tumour
truly had an invasive histology (n = 37). The diagnosis
date was defined as the date at which clinical mammog-
raphy was performed (n = 2655). When this date was un-
available, the date was set at 1 month prior to surgery
(n = 77) or the date was obtained from the pathology re-
port (n = 10). Women were excluded from the study
when these dates were missing (n = 11). Information on
vital status and cause of death were obtained via linkage
with municipality records.
Women were followed from their diagnosis date until
date of death, date of moving out of the area, or the end
of study follow-up (December 31st, 2011). Follow-up
was not always complete: it was unclear if some women
were still alive, but no report of relocation or death was
available (n = 652). The end date was then set at the year
after the last screening invitation for a sensitivity ana-
lysis. We studied the effect of this censoring on the
estimates.
Mode of detection was categorised into screen-
detected, interval, and non-participant cancer. Screen-
detected cancer was defined as all diagnoses after a posi-
tive screening exam. Interval cancer was further divided
into tumours occurring within 24 months (≤24 m) and
more than 24 months (> 24 m) after a negative screening
exam. The category ‘non-participant cancer’ consists of
cancer diagnoses in women who never participated in
breast cancer screening.
Breast density
Screening is based on two-view mammography at first
examination: mediolateral oblique (MLO) and cranio-
caudal (CC). In the time period that we studied, subse-
quent exams consisted of one view (MLO), with the CC
view being used on indication. Digital mammography
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was introduced in the Nijmegen screening programme
in 2007. Density was, however, only assessed on film-
screen mammograms.
Breast density was assessed visually by a trained re-
search assistant. These assessments were based on all
available mammography views. A quantified version of
the Wolfe breast pattern scale was used, which consisted
of the following categories: (1) < 5%, (2) 5–25%, (3) 26–
75%, and (4) > 75% breast density. This scale was dichot-
omized for all analyses into ‘fatty breasts’ (≤25%) and
‘dense breasts’ (> 25%). A previous study has shown that
there is a strong correlation between the Wolfe and the
BI-RADS scale [30]. Breast density measurements were
based on the last screening round before diagnosis (n =
1515). If this was not available, breast density was based
on the diagnostic mammogram (n = 612) or the round
preceding the last screening round (n = 106). Women
were excluded from the analyses on breast density when
no breast pattern was available in our dataset (n = 509).
Statistical analyses
Cox proportional hazard regression was used to assess
the effect of breast density on breast cancer-specific sur-
vival. We thus report cause-specific survival estimates,
rather than e..g. overall survival or disease-free survival.
Breast density was included as a determinant in the ana-
lyses. This resulted in hazard ratios (HR) and corre-
sponding 95% confidence intervals (CI). The time scale
was from time of diagnosis to date of breast cancer
death. Analyses were stratified by mode of detection. All
analyses were corrected for age at diagnosis.
Kaplan-Meier curves were examined and time-
dependent covariates were included in the regression
model to test the proportional hazards assumptions. All
tests were two-sided, with a p-value < 0.05 being consid-
ered statistically significant. The analyses were per-
formed with SPSS 22.0.
Results
We identified 2742 eligible women with an invasive
tumour, with a breast pattern available for 2233 women.
The age at diagnosis ranged from 38 to 97 years. Most
women had a fatty breast pattern (n = 1456, 65.2%).
There were 536 breast cancer deaths in this population.
Breast density was known for 479 breast cancer deaths,
of whom 173 (36.1%) had dense breasts. There were 149
breast cancer deaths among the 1257 screen-detected
cases, 129 among the 557 interval cases ≤24 m, 154
among the 604 interval cases > 24 m, and 104 among
the 324 non-participant cases.
Breast cancer-specific survival by detection mode
The age-adjusted effect of detection mode on breast
cancer-specific survival is presented in Table 1. Screen-
detected cancer was used as the reference category. A
diagnosis of interval cancer ≤24 m (age-adjusted HR
2.06, 95% CI 1.62–2.61), interval cancer > 24 m (age-ad-
justed HR 3.00, 95% CI 2.37–3.79), and non-participant
cancer (age-adjusted HR 4.18, 95% CI 3.25–5.39) led
to a significantly poorer breast cancer-specific survival
compared with screen-detected cancer.
Breast cancer-specific survival by breast density
As shown in Table 2, there was no significant difference
in breast cancer-specific survival between dense and
fatty breasts when all detection modes were combined
(age-adjusted HR 0.94, 95% CI 0.77–1.15). The hazard
was only slightly higher for women with dense breasts
among interval tumours ≤24 m (age-adjusted HR 1.07,
95% CI 0.74–1.56). The hazard appeared to be lower
in women with dense breasts than fatty breasts
among screen-detected (age-adjusted HR 0.77, 95% CI
0.53–1.11) and interval tumours > 24 m (age-adjusted
HR 0.80, 95% CI 0.53–1.20). When screen-detected
and interval tumours ≤24 m were combined, there
appeared to be no difference in hazard (age-adjusted
HR 1.01, 95% CI 0.78–1.31). None of the effects were,
however, statistically significant. Adjustment of the over-
all effect for age and mode of detection resulted in a HR
of 0.84 (95% CI 0.68–1.03), possibly suggesting an inverse
association between high breast density and breast
cancer-specific survival.
Additional adjustment for year of diagnosis did not
change the estimates (data not shown). Furthermore,
sensitivity analyses showed that censoring the follow-up
after last invitation in women with apparent loss to
follow-up had no effect on the estimates (data not
shown).
Discussion
There was no clear overall association between breast
density and breast cancer-specific survival. A high breast
density might lead to missed detection and thus a later
stage at diagnosis, when tumours are harder to treat (i.e.
a true worsening of survival). Since screen-detected tu-
mours are relatively less frequent in women with dense
breasts due to missed detection, however, survival esti-
mates are less affected by lead and length time bias in
women with high breast density. These biases make sur-
vival associated with low breast density appear better,
thus further increasing the difference in breast cancer-
specific survival. By adjusting for mode of detection, we
attempted to remove lead and length time bias from our
association. This adjustment, however, also removed that
part of the true association between breast density and
breast cancer-specific survival due to missed detection’s
influence on later stage at diagnosis and subsequent
worse survival. The possible inverse association between
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breast density and breast cancer-specific survival after
adjustment would thus have to be attributed to other
factors.
Breast cancer-specific survival in interval cancer is al-
ways expected to be worse than in screen-detected cancer
[31]. The difference in breast cancer-specific survival (HR
2.06, 95% CI 1.62–2.61) may partly be explained by lead
or length time bias, resulting in an artificial increase in
survival time due to the advanced diagnosis in screen-
detected cancer or the detection of slow-growing tumours.
The remaining breast cancer-specific survival difference
would be explained by a better prognosis as a result of
early detection. Detection mode was previously shown to
give important prognostic information, even after adjust-
ment for well-known prognostic characteristics [32].
The distribution of interval and screen-detected tu-
mours is expected to differ between women with high and
low breast density. As a result of the masking effect of
dense tissue and subsequent missed detection, the risk of
interval tumours is higher [20, 33–36]. Tumours are thus
detected at a later stage, when they are harder to treat.
Newer mammography systems are expected to decrease
the masking effect. Although mammographic technology
has greatly evolved between 1975 and 2011, adjustment
for year of diagnosis did not appear to alter the estimates
(results not shown). This suggests that the association, or
rather lack of association, is consistent over time.
After adjusting the overall estimates for detection
mode, women with dense breasts appeared to have a
survival advantage compared to women with fatty
breasts. This potential inverse association between breast
density would have to be explained by other factors than
missed detection, e.g. an inverse association with tumour
aggressiveness, but we have to be cautious with the in-
terpretation of these results. There are several studies on
the association between breast density and prognostic
Table 1 Breast cancer-specific survival by detection mode
Person years N totala N breast cancer deaths (%) HR adjusted for age (95% CI) P-value
Screen-detected cancer 13,183 1257 149 (11.9) 1.00 (Ref.)
Interval cancer ≤24 months 5627 557 129 (23.2) 2.06 (1.62–2.61) < 0.001
Interval cancer > 24 months 4299 604 154 (25.5) 3.00 (2.37–3.79) < 0.001
Non-participant cancer 2097 324 104 (32.1) 4.18 (3.25–5.39) < 0.001
a Follow-up time of 11 participants was censored before the first death occurred in the stratum
Table 2 Breast cancer-specific survival by breast density and mode of detection
Person
years
N
totala
N breast cancer
deaths (%)
HR adjusted for age
(95% CI)b
P-value HR adjusted for age and mode
of detection (95% CI)b
P-value
Overall
Dense 9418 777 173 (22.3) 0.94 (0.77–1.15) 0.58 0.84 (0.68–1.03) 0.09
Fatty 14,495 1456 306 (21.0) 1.00 (Ref.) 1.00 (Ref.)
Screen-detected + Interval cancer≤ 24 m
Dense 7424 595 115 (19.3) 1.01 (0.78–1.31) 0.91
Fatty 10,995 995 162 (16.3) 1.00 (Ref.)
Screen-detected cancer
Dense 4329 340 44 (12.9) 0.77 (0.53–1.11) 0.16
Fatty 8589 760 105 (13.8) 1.00 (Ref.)
Interval cancer≤ 24 m
Dense 3095 255 71 (27.8) 1.07 (0.74–1.56) 0.72
Fatty 2406 235 57 (24.3) 1.00 (Ref.)
Interval cancer > 24 m
Dense 1433 133 41 (30.8) 0.80 (0.53–1.20) 0.29
Fatty 2334 290 86 (29.7) 1.00 (Ref.)
Non-participant cancer
Dense 562 49 17 (34.7) 0.72 (0.40–1.31) 0.29
Fatty 1166 171 58 (33.9) 1.00 (Ref.)
a Follow-up time of several participants was censored before the first death occurred in the stratum. Overall: n = 4; Screen-detected+Interval cancer ≤24 m: n = 8;
Screen-detected cancer: n = 5; Interval cancer ≤24 m: n = 4; Interval cancer > 24 m: n = 1; Non-participant cancer: n = 1
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tumour characteristics [3–7, 13–18]. Results on associa-
tions with tumour markers of aggressiveness, e.g. hor-
mone receptor status, appear to be inconclusive. Some
studies observed associations with tumour markers of
progression, e.g. large tumour size and lymph node in-
volvement, which may be a consequence of late detec-
tion. Most studies were not able to differentiate between
screen-detected and interval tumours, thus limiting con-
clusions that may be drawn on the contribution of late
detection to these associations.
Several previous studies have addressed the association
between breast density and breast cancer mortality or
breast cancer-specific survival, with large variation in de-
sign, outcomes, and conclusions (Table 3) [20–28]. Olsson
et al. was the only one to stratify by mode of detection
[21]. Dense breasts appeared to be associated with an in-
creased risk of breast cancer death in symptomatic and
non-symptomatic tumours. Gierach et al. adjusted for
mode of detection in the fully adjusted model, but they
did not present the stratified results [25]. They found no
significant difference in breast cancer-specific survival be-
tween dense and fatty breasts. This was true for most
other studies as well. Olsen et al. found a higher mortality
for dense breasts, but case fatality appeared to be lower
[20]. Six studies presented estimates that were adjusted
for indicators of tumour progression and/or type of treat-
ment. These adjustments are likely to remove (a large part
of) the negative effect of missed detection on breast
cancer-specific survival as well. Assuming that there is no
biological association with tumour aggressiveness, the ad-
justed estimates are expected to show no effect. Olsson et
al. and Chiu et al., however, found the opposite: the
already positive hazard ratios further increased after these
adjustments [21, 27]. Maskarinec et al. and Zhang et al.
only presented adjusted estimates, which suggested no ef-
fect [26, 28]. This was in line with the findings from Gier-
ach and colleagues [25].
Stratification by detection mode removes, or at least re-
duces, the effects of missed detection, lead time bias, and
length time bias. In the resulting groups (i.e. screen-
detected and interval cancer), there are still other effects
that need to be considered. A substantial number of inter-
val tumours in the first year after screening in women
with high density may actually be slow-growing tumours
that were masked during screening (i.e. false-negative re-
sults). The first-year interval tumours in women with a
low breast density, on the other hand, could be more ag-
gressive fast-growing tumours. Delayed detection due to
high breast density could also still have some influence on
observed breast cancer-specific survival in symptomatic
cases. Furthermore, excessive opportunistic screening pro-
vides a challenge in differentiating between symptomatic
and non-symptomatic tumours. Opportunistic screening
refers to screening activities that take place outside the
organised screening programme. For example, asymptom-
atic women may ask their GP for a referral to the hospital
rather than or even in addition to attending the regular
screening programme. These women are classified as
non-participants, despite participating in ‘opportunistic
screening’. Previous research has shown that opportunistic
screening occurs frequently [37], and this may have also
affected our estimates for the non-participants.
Our study had some limitations. We used a qualitative
method to measure breast density, which may have led
to non-differential misclassification. Breast pattern was
also missing in a relatively large group. This was mainly
the result of the introduction of digital mammography.
Digital mammography was introduced in the clinic sev-
eral years before it was introduced in the Dutch screen-
ing programme. Breast density pattern was therefore
more often missing for ‘interval tumours > 24 m’ and
‘non-participant’ tumours than for ‘screen-detected’ or
‘interval ≤ 24 m’ tumours. It seems unlikely, however,
that the missing data is associated with breast density
status or breast cancer death. Another limitation is the
lack of potential confounder data. We only have accurate
and complete information on age at diagnosis and year
of diagnosis. We did, however, stratify by mode of detec-
tion, which can also be seen as a proxy method for deal-
ing with lead and length time bias. Finally, a certain
degree of informative censoring may have potentially af-
fected our findings.
Conclusions
Detection mode undoubtedly has a strong association
with breast cancer death, but there is no clear associ-
ation between breast density and breast cancer death.
This is regardless of detection mode. Breast density is
known to affect screening performance and screening
decreases the risk of breast cancer death. Further re-
search is still, however, needed on the interplay between
breast density, detection mode, and breast cancer-
specific survival. Disentangling the different components
that influence the observed association between breast
density and breast cancer survival will provide new in-
sights into the potential role of breast density in both
tumour biology and early detection.
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